beta amyloid
GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal
GlaxoSmithKline Biologicals and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.
As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and [...]
Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal
Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an agreement to develop products from CoMentis’ beta-secretase inhibitor program, including the recently initiated, phase 2, lead candidate compound CTS-21166, an oral beta-secretase inhibitor for the treatment of Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase [...]
Recent Comments